XRAY
DENTSPLY SIRONA Inc. NASDAQ$11.81
After hrs
$11.26
+0.49%
Mkt Cap $2.4B
52w Low $9.85
26.7% of range
52w High $17.18
50d MA $12.19
200d MA $12.66
P/E (TTM)
-3.9x
EV/EBITDA
-96.1x
P/B
1.8x
Debt/Equity
1.8x
ROE
-44.7%
P/FCF
21.9x
RSI (14)
—
ATR (14)
—
Beta
1.00
50d MA
$12.19
200d MA
$12.66
Avg Volume
4.5M
About
DENTSPLY SIRONA Inc. manufactures and sells various dental products and technologies for professional dental market worldwide. The company operates through two segments, Technologies & Equipment, and Consumables. The Technologies & Equipment segment provides dental equipment, such as treatment centers, imaging equipment, motorized dental handpieces, and other instruments for dental practitioners a…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | AMC | 0.28 | 0.27 | -3.6% | 12.71 | +2.7% | +15.5% | +12.6% | +4.6% | +5.7% | +4.9% | -11.9% | — |
| Nov 6, 2025 | AMC | 0.45 | 0.37 | -17.8% | 11.02 | -1.8% | +1.5% | -0.2% | -0.4% | -1.6% | -0.6% | +0.7% | — |
| Aug 7, 2025 | AMC | 0.50 | 0.52 | +4.0% | 13.23 | -0.8% | -2.0% | -5.3% | -1.4% | +4.7% | +4.8% | +7.4% | — |
| May 8, 2025 | AMC | 0.29 | 0.43 | +48.3% | 15.91 | -0.4% | -0.6% | +5.3% | +4.3% | +3.4% | +3.7% | +2.0% | — |
| Feb 27, 2025 | AMC | 0.47 | 0.26 | -44.7% | 17.15 | +0.0% | -3.5% | -6.8% | -9.1% | -5.8% | -5.2% | -12.9% | — |
| Nov 7, 2024 | AMC | 0.48 | 0.50 | +4.2% | 17.26 | +1.9% | +3.5% | +2.3% | +3.0% | +0.5% | +3.5% | +12.7% | — |
| Jul 31, 2024 | AMC | 0.50 | 0.49 | -2.0% | 27.14 | +0.4% | -1.5% | -6.1% | -9.8% | -11.0% | -12.9% | -6.8% | — |
| May 2, 2024 | AMC | 0.42 | 0.42 | +0.0% | 28.38 | +1.3% | -0.3% | -0.5% | -0.5% | -2.0% | -0.6% | -1.2% | — |
| Feb 29, 2024 | AMC | 0.43 | 0.44 | +2.3% | 32.68 | +0.9% | +1.8% | +1.8% | +1.8% | +2.2% | +2.3% | -1.3% | — |
| Nov 2, 2023 | AMC | 0.48 | 0.49 | +2.1% | 28.54 | +0.8% | +2.3% | +0.1% | -0.5% | -3.0% | -4.5% | +14.7% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 2 | Barrington Research | Maintains | Outperform → Outperform | — | $14.68 | $14.39 | -2.0% | -2.5% | -9.4% | -8.4% | -9.2% | -13.2% |
| Mar 2 | Mizuho | Maintains | Neutral → Neutral | — | $14.68 | $14.39 | -2.0% | -2.5% | -9.4% | -8.4% | -9.2% | -13.2% |
| Feb 27 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $12.71 | $13.05 | +2.7% | +15.5% | +12.6% | +4.6% | +5.7% | +4.9% |
| Feb 27 | Baird | Maintains | Neutral → Neutral | — | $12.71 | $13.05 | +2.7% | +15.5% | +12.6% | +4.6% | +5.7% | +4.9% |
| Feb 27 | Evercore ISI | Maintains | In Line → In Line | — | $12.71 | $13.05 | +2.7% | +15.5% | +12.6% | +4.6% | +5.7% | +4.9% |
| Feb 19 | BofA Securities | Upgrade | Neutral → Buy | — | $12.49 | $13.12 | +5.0% | +0.2% | +0.4% | +0.5% | +5.2% | +2.5% |
| Feb 3 | UBS | Maintains | Buy → Buy | — | $12.21 | $12.18 | -0.2% | -1.7% | +2.7% | +2.6% | +12.7% | +12.2% |
| Jan 20 | Mizuho | Maintains | Neutral → Neutral | — | $12.21 | $12.00 | -1.7% | -1.3% | +4.3% | +6.5% | +4.3% | +4.2% |
| Jan 5 | Barrington Research | Maintains | Outperform → Outperform | — | $11.27 | $11.30 | +0.3% | +3.0% | +9.8% | +9.8% | +10.7% | +13.4% |
| Dec 16 | Barrington Research | Maintains | Outperform → Outperform | — | $11.40 | $11.35 | -0.4% | -0.3% | +0.3% | -1.1% | -1.7% | -1.2% |
Recent Filings
8-K
DENTSPLY SIRONA Inc. -- 8-K Filing
DENTSPLY SIRONA strengthened its board with three experienced executives from dental and financial sectors, including Morgan Stanley's former investment banking leader and IDEXX's ex-CFO, signaling potential strategic shifts ahead.
Feb 26
8-K · 5.02
!!! Very High
DENTSPLY SIRONA Inc. -- 8-K 5.02: Executive Change
DENTSPLY SIRONA appointed James D. Forbes as director while Willie A. Deese resigned, signaling potential strategic shifts in board composition and governance priorities.
Feb 24
8-K · 5.02
!!! Very High
Charles River Laboratories International, Inc. -- 8-K 5.02: Executive Change
Charles River Laboratories appointed Glenn Coleman as Corporate Executive Vice President and Chief Financial Officer, effective April 6, 2026, signaling leadership stability in financial operations.
Feb 18
Data updated apr 27, 2026 10:52am
· Source: massive.com